Cas:76148-93-1 3-(4-methoxyphenyl)-2H-1,4-benzothiazine manufacturer & supplier

Chemical Name:3-(4-methoxyphenyl)-2H-1,4-benzothiazine

CAS.NO:76148-93-1

Synonyms:3-(4-METHOXY-PHENYL)-2H-BENZO[1,4]THIAZINE;3-(p-methoxyphenyl)-2H-1,4-benzothiazine;2H-1,4-Benzothiazine,3-(4-methoxyphenyl);3-[4-(methyloxy)phenyl]-2H-1,4-benzothiazine;GL-0674

Molecular Formula:C₁₅H₁₃NOS

Molecular Weight:255.33500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:389.6ºC at 760 mmHg

Density:1.19g/cm3

Index of Refraction:1.631

PSA:46.89000

Exact Mass:255.07200

LogP:3.35730

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-(4-METHOXY-PHENYL)-2H-BENZO[1,4]THIAZINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,GL-0674 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(p-methoxyphenyl)-2H-1,4-benzothiazine Use and application,3-(4-METHOXY-PHENYL)-2H-BENZO[1,4]THIAZINE technical grade,usp/ep/jp grade.

Related News: It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. 3-(4-methoxyphenyl)-2H-1,4-benzothiazine manufacturer In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine. 3-(4-methoxyphenyl)-2H-1,4-benzothiazine supplier The Wuhan coronavirus has brought back memories of the 2003 outbreak of the severe acute respiratory syndrome, known as SARS, which infected more than 8,000 people and killed 774. 3-(4-methoxyphenyl)-2H-1,4-benzothiazine vendor The Wuhan coronavirus has brought back memories of the 2003 outbreak of the severe acute respiratory syndrome, known as SARS, which infected more than 8,000 people and killed 774. 3-(4-methoxyphenyl)-2H-1,4-benzothiazine factory Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access.